Wild-type Huntingtin protects from apoptosis upstream of caspase-3

被引:294
作者
Rigamonti, D
Bauer, JH
De-Fraja, C
Conti, L
Sipione, S
Sciorati, C
Clementi, E
Hackam, A
Hayden, MR
Li, Y
Cooper, JK
Ross, CA
Govoni, S
Vincenz, C
Cattaneo, E
机构
[1] Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Hosp San Raffaele, Dept Biotechnol, I-20132 Milan, Italy
[4] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy
[5] Univ British Columbia, Vancouver, BC V52 4H4, Canada
[6] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD 21205 USA
[7] Univ Pavia, Inst Pharmacol, I-27100 Pavia, Italy
关键词
huntingtin; CAG; caspases; survival; CNS cells; Huntington's disease;
D O I
10.1523/JNEUROSCI.20-10-03705.2000
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Expansion of a polyglutamine sequence in the N terminus of huntingtin is the gain-of-function event that causes Huntington's disease. This mutation affects primarily the medium-size spiny neurons of the striatum. Huntingtin is expressed in many neuronal and non-neuronal cell types, implying a more general function for the wild-type protein. Here we report that wild-type huntingtin acts by protecting CNS cells from a variety of apoptotic stimuli, including serum withdrawal, death receptors, and pro-apoptotic Bcl-2 homologs. This protection may take place at the level of caspase-9 activation. The full-length protein also modulates the toxicity of the poly-Q expansion. Cells expressing full-length mutant protein are susceptible to fewer death stimuli than cells expressing truncated mutant huntingtin.
引用
收藏
页码:3705 / 3713
页数:9
相关论文
共 43 条
  • [11] INACTIVATION OF THE MOUSE HUNTINGTONS-DISEASE GENE HOMOLOG HDH
    DUYAO, MP
    AUERBACH, AB
    RYAN, A
    PERSICHETTI, F
    BARNES, GT
    MCNEIL, SM
    GE, P
    VONSATTEL, JP
    GUSELLA, JF
    JOYNER, AL
    MACDONALD, ME
    [J]. SCIENCE, 1995, 269 (5222) : 407 - 410
  • [12] Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
    Goldberg, YP
    Nicholson, DW
    Rasper, DM
    Kalchman, MA
    Koide, HB
    Graham, RK
    Bromm, M
    KazemiEsfarjani, P
    Thornberry, NA
    Vaillancourt, JP
    Hayden, MR
    [J]. NATURE GENETICS, 1996, 13 (04) : 442 - 449
  • [13] GORCZYCA W, 1993, CANCER RES, V53, P3186
  • [14] Gutekunst CA, 1999, J NEUROSCI, V19, P2522
  • [15] The influence of Huntingtin protein size on nuclear localization and cellular toxicity
    Hackam, AS
    Singaraja, R
    Wellington, CL
    Metzler, M
    McCutcheon, K
    Zhang, TQ
    Kalchman, M
    Hayden, MR
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 141 (05) : 1097 - 1105
  • [16] A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
    Hodgson, JG
    Agopyan, N
    Gutekunst, CA
    Leavitt, BR
    LePiane, F
    Singaraja, R
    Smith, DJ
    Bissada, N
    McCutcheon, K
    Nasir, J
    Jamot, L
    Li, XJ
    Stevens, ME
    Rosemond, E
    Roder, JC
    Phillips, AG
    Rubin, EM
    Hersch, SM
    Hayden, MR
    [J]. NEURON, 1999, 23 (01) : 181 - 192
  • [17] Kim M, 1999, J NEUROSCI, V19, P964
  • [18] Neuronal intranuclear inclusions in polyglutamine diseases: Nuclear weapons or nuclear fallout?
    Kim, TW
    Tanzi, RE
    [J]. NEURON, 1998, 21 (04) : 657 - 659
  • [19] PATTERNS OF CELL LOSS IN HUNTINGTONS-DISEASE
    KOWALL, NW
    FERRANTE, RJ
    MARTIN, JB
    [J]. TRENDS IN NEUROSCIENCES, 1987, 10 (01) : 24 - 29
  • [20] Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum
    Lundberg, C
    MartinezSerrano, A
    Cattaneo, E
    McKay, RDG
    Bjorklund, A
    [J]. EXPERIMENTAL NEUROLOGY, 1997, 145 (02) : 342 - 360